Acknowledgment
- PDF / 49,482 Bytes
- 2 Pages / 592.44 x 751.18 pts Page_size
- 3 Downloads / 173 Views
ACKNOWLEDGMENT
© 2007 Adis Data Information BV. All rights reserved.
Dear Reader, Once again we have reached the final issue of the year for Molecular Diagnosis & Therapy, and we hope that you have found the articles published throughout 2007 to be both interesting and informative. The editors and publishing staff have appreciated the high quality of content contributed to the journal this year, and the forward program for 2008 looks set to build on these standards as we continue to keep you up to date with topical issues in molecular diagnostics, pharmacogenomics, and personalized medicine. As you are aware, the market for, and availability of, molecular diagnostics, companion diagnostics, and pharmacogenetic testing is broadening at a rapid rate. To keep you informed of the latest advances and to provide accurate and up-to-date information on the expanding number of tests approaching the market place, we are establishing a new, structured article type to profile new diagnostic tests either after approval or in late-stage clinical development. These Diagnostic Profile articles are set to be published starting from the first issue of 2008 and, where possible, will be accompanied by Commentary articles by independent experts. We are also pleased to advise you of a number of important developments to affect the Wolters Kluwer Health | Adis journals portfolio in 2007. This year saw the implementation of our manuscript tracking system Editorial Managerâ„¢, which has streamlined the publishing process for authors, reviewers and editors alike. The new system can be accessed at http://www.editorialmanager.com/adis/ default.asp and we invite you to use it when submitting your manuscripts to Molecular Diagnosis & Therapy in the future. The year has brought further recognition of the quality of a number of our titles, with new ISI impact factors reflecting our global standing. Sports Medicine, our premier sports medicine review journal, was ranked number one in the Sports Science category, with an impact factor of 3.504. Also worthy of mention, BioDrugs increased its impact factor to 2.768, Drugs increased to 4.472, CNS Drugs to 4.210, and Drug Safety to 3.673. A number of significant articles published in Adis journals in 2007 reflect important collaborations with leading scientists from both academia and industry. Drug Safety published Guidelines for Submitting Adverse Event Reports for Publication, an important collaborative effort between the journal staff and the International Societies of Pharmacoepidemiology (ISPE) and Pharmacovigilance (ISoP). Sports Medicine was selected to publish the proceedings of the 2006 World Congress on the Science and Medicine of the Marathon and the International Journal of Pharmaceutical Medicine worked in tandem with the European Forum for Good Clinical Practice to produce the first comprehensive report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in the European Union. We are also pleased to announce the launch of a new title in the Adis portfolio.
Data Loading...
